Urine titin as a novel biomarker for Duchenne muscular dystrophy
Neuromuscular Disorders · 2023-04 · 33 (4) · 302-308
DOI: 10.1016/j.nmd.2023.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuromuscular Disorders, 2023-04. Verfasst von Misawa Niki Ishii und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Tokyo, 251-0012, 26-1, 2-chome, Higashimuraoka, Fujisawa, Kanagawa, Japan. E…. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is the most severe form of muscular dystrophy that is caused by lack of dystrophin, a critical structural protein in skeletal muscle. DMD treatments, and quantitative biomarkers to assess the efficacy of potential treatments, are urgently needed. Previous evidence has shown that titin, a muscle cell protein, is increased in the urine of patients with DMD, suggesting its usefulness as a DMD biomarker. Here, we demonstrated that the elevated titin in urine is directly associated with the lack of dystrophin and urine titin responses to drug treatment. We performed a drug intervention study using mdx mice, a DMD mouse model. We showed that mdx mice, which lack dystrophin due to a mutation in exon 23 of the Dmd gene, have elevated urine titin. Treatment with an exon skipper that targets exon 23 rescued muscle dystrophin level and dramatically decreased urine titin in mdx mice and correlates with dystrophin expression. We also demonstrated that titin levels were significantly increased in the urine of patients with DMD. This suggests that elevated urine titin level might be a hallmark of DMD and a useful pharmacodynamic marker for therapies designed to restore dystrophin levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Tokyo, 251-0012, 26-1, 2-chome, Higashimuraoka, Fujisawa, Kanagawa, Japan. Electronic address: misawa.ishii@takeda.com.
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Tokyo, 251-0012, 26-1, 2-chome, Higashimuraoka, Fujisawa, Kanagawa, Japan.
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, US, 350 Massachusetts Ave Cambridge, MA 02139, United Kingdom.
Zitieren
APA
Ishii, M. N., Nakashima, M., Kamiguchi, H., Zach, N., Kuboki, R., Baba, R., Hirakawa, T., Suzuki, K., & Quinton, M. (2023). Urine titin as a novel biomarker for Duchenne muscular dystrophy. Neuromuscular Disorders, 33(4), 302-308. https://doi.org/10.1016/j.nmd.2023.02.003
Vancouver
Ishii MN, Nakashima M, Kamiguchi H, Zach N, Kuboki R, Baba R, et al. Urine titin as a novel biomarker for Duchenne muscular dystrophy. Neuromuscular Disorders. 2023;33(4):302-308. doi:10.1016/j.nmd.2023.02.003
BibTeX
@article{Ishii2023,
author = {Ishii, Misawa Niki and Nakashima, Masato and Kamiguchi, Hidenori and Zach, Neta and Kuboki, Ryosuke and Baba, Rina and Hirakawa, Takeshi and Suzuki, Kazunori and Quinton, Maria},
title = {Urine titin as a novel biomarker for Duchenne muscular dystrophy},
journal = {Neuromuscular Disorders},
year = {2023},
volume = {33},
number = {4},
pages = {302--308},
doi = {10.1016/j.nmd.2023.02.003}
}
EUVIMED